Four blockbuster GLP-1 medications are expected to be among the 10 best-selling drugs in 2026, accounting for $66.8 billion in global sales, according to market research company Statista
Statista predicts Ozempic will yield $22.3 billion in 2026, followed by Mounjaro with $19.8 billion, Wegovy with $13.4 billion and Zepbound with $11.3 billion.
Here are six recent updates on the lucrative drug class:
1. Novo Nordisk’s experimental obesity medication CagriSema could lead to 15.7% weight loss over 68 weeks — significantly lower than the company’s projection of 25% weight loss. On March 10, the company said it plans to seek regulatory approval for the drug in early 2026.
2. Longevity clinics are tapping into the GLP-1 market and marketing the medications for anti-aging purposes. Ongoing studies are examining how the drug class might affect age-related conditions including Alzheimer’s disease, osteoarthritis and some cancers.
3. Citing high prescription drug costs, particularly among GLP-1s, Highmark Health Plans reported a $166 million operating loss for 2024. Several other insurers have said GLP-1s are a key factor in their operating losses.
4. A University of Chicago-led study analyzed the cost-effectiveness of Wegovy and Zepbound, which are both approved for weight loss. To be considered cost-effective, researchers said Wegovy’s price would need to fall by more than 80% to $127 per month, and Zepbound would need to drop by nearly one-third to $361 per month.
5. For the first time, GLP-1 medications surpassed specialty drugs in 2024 expenditures, according to a March 25 report from Evernorth. Weight loss drugs accounted for 46.8% of the total increase in drug spending and made up 6.7% of total drug costs. GLP-1s for weight loss saw a 210.2% spending increase in 2023 and a 148.7% increase in 2024.
6. On March 26, compounding pharmacies are no longer permitted to manufacture exact copies of Zepbound, per an FDA deadline.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
